Live Breaking News & Updates on Semmes Distinguished University Chair|Page 3

Stay updated with breaking news from Semmes distinguished university chair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NervGen Pharma Corp.: NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models

NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's Disease
Vancouver, British Columbia (Newsfile Corp. - June 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" ....

United States , United Kingdom , British Columbia , San Antonio , University Of Texas , Noord Holland , Kostenloser Wertpapierhandel , Paul Brennan , Nancy Thompson , George Perry , Huitt Tracey , Linkedin Nervgen Pharma Corp , Sylics Contract Research , British Columbia Newsfile Corp , Nervgen Pharma Corp , Company Annual Information Form , Semmes Distinguished University , Corporate Communications , Venture Exchange , Regulation Services Provider , Nervgen Preparing , Upcoming Phase , Clinical Trial , Gen Pharma , Daniel Mikol , Chief Medical ,

Meditative practice and spiritual wellbeing may preserve cognitive function in aging

E-Mail
IMAGE: The overall relationship between spiritual fitness and a person s complete physical and mental health.
view more
Credit: Dr. Khalsa and Dr. Newberg
Amsterdam, May 11, 2021 - It is projected that up to 152 million people worldwide will be living with Alzheimer s disease (AD) by 2050. To date there are no drugs that have a substantial positive impact on either the prevention or reversal of cognitive decline. A growing body of evidence finds that targeting lifestyle and vascular risk factors have a beneficial effect on overall cognitive performance. A new review in the
Journal of Alzheimer s Disease, published by IOS Press, examines research that finds spiritual fitness, a new concept in medicine that centers on psychological and spiritual wellbeing, and Kirtan Kriya, a simple 12-minute meditative practice, may reduce multiple risk factors for AD. ....

United States , San Antonio , Thomas Jefferson University , Noord Holland , University Of Texas At San Antonio , Dharma Singh Khalsa , Kirtan Kriya , Andrewb Newberg , George Perry , Singh Khalsa , Alzheimer Research , Department Of Radiology , Marcus Institute Of Integrative Health , Prevention Foundation , Semmes Distinguished University , Nutritional Sciences , Department Of Integrative Medicine , Integrative Medicine , Marcus Institute , Integrative Health , Semmes Distinguished University Chair , ஒன்றுபட்டது மாநிலங்களில் , சான் அன்டோனியோ , தாமஸ் ஜெஃபர்சன் பல்கலைக்கழகம் , நூற்த் ஹாலண்ட் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் இல் சான் அன்டோனியோ ,

Spiritual fitness and meditative practice may reduce multiple risk factors for Alzheimer's disease

Spiritual fitness and meditative practice may reduce multiple risk factors for Alzheimer s disease
It is projected that up to 152 million people worldwide will be living with Alzheimer s disease (AD) by 2050. To date there are no drugs that have a substantial positive impact on either the prevention or reversal of cognitive decline. A growing body of evidence finds that targeting lifestyle and vascular risk factors have a beneficial effect on overall cognitive performance. A new review in the
Journal of Alzheimer s Disease, published by IOS Press, examines research that finds spiritual fitness, a new concept in medicine that centers on psychological and spiritual wellbeing, and Kirtan Kriya, a simple 12-minute meditative practice, may reduce multiple risk factors for AD. ....

United States , San Antonio , Thomas Jefferson University , University Of Texas At San Antonio , Dharma Singh Khalsa , Kirtan Kriya , Andrewb Newberg , George Perry , Singh Khalsa , Emily Henderson , Alzheimer Research , Department Of Radiology , Marcus Institute Of Integrative Health , Prevention Foundation , Semmes Distinguished University , Nutritional Sciences , Department Of Integrative Medicine , Integrative Medicine , Marcus Institute , Integrative Health , Semmes Distinguished University Chair , ஒன்றுபட்டது மாநிலங்களில் , சான் அன்டோனியோ , தாமஸ் ஜெஃபர்சன் பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் இல் சான் அன்டோனியோ , தர்மம் சிங் கல்ச ,

NervGen Pharma Corp.: NervGen Pharma Reports 2020 Year End Results

NervGen Pharma Corp.: NervGen Pharma Reports 2020 Year End Results
Vancouver, British Columbia (Newsfile Corp. - April 8, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.
Paul Brennan, NervGen s President & CEO, stated, We made substantial progress in the development of our lead program, NVG-291, towards clinical trials during 2020. We were able to resubmit our Investigational New Drug Application for NVG-291 early in 2021 and we look forward to starting our Phase 1 trial in Australia this quarter. We continue to generate encouraging preclinical data to support our programs to bring life-changing hope to many people suffering from nerve damage as a result of injury or neurodegenerative diseases. Pending successful completion of our ....

United States , San Antonio , United Kingdom , University Of Texas , British Columbia , Brian Mcalister , Paul Brennan , Lloyd Mackenzie , Nancy Thompson , Randall Kaye , Denis Bosc , Michael Davis , George Perry , Kostenloser Wertpapierhandel , Huitt Tracey , Program Management , Linkedin Nervgen Pharma Corp , Novotech Australia Pty , Nervgen Pharma Corp , Venture Exchange , Regulation Services Provider , Drug Administration , British Columbia Newsfile Corp , Company Annual Information Form , Semmes Distinguished University , Us Combat Casualty Care Research Program ,

NervGen Pharma Corp.: NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Board

NervGen Pharma Corp.: NervGen Pharma Establishes Alzheimer s Disease Scientific Advisory Board
Vancouver, British Columbia (Newsfile Corp. - January 26, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer s Disease Scientific Advisory Board ( AD-SAB ) with the appointment of four world-class scientists and clinical researchers in Alzheimer s disease: Jeffrey Cummings, MD, ScD; George Perry, PhD; Henrik Zetterberg, MD, PhD; and Bruce Lamb, PhD. The AD-SAB will work closely with NervGen as the Company plans its upcoming preclinical studies and clinical trials and in the analyses of the results from these studies. ....

United States , United Kingdom , British Columbia , San Diego , San Antonio , University Of Texas , Bruce Lamb , Paul Brennan , Henrik Zetterberg , George Perry , Las Vegas , Kostenloser Wertpapierhandel , Erikk Fernstr , Jeffrey Cummings , Santa Barbara , Huitt Tracey , University College London , American Association Of Geriatric Psychiatry , Nervgen Pharma Corp , Head Of The Department Psychiatry , Sahlgrenska University Hospital , University Of Nevada , Venture Exchange , Regulation Services Provider , American Geriatrics Society , British Columbia Newsfile Corp ,